
In November 2015, the company said it had received a warning letter from the US Food and Drug Administration (USFDA) for three of its sites -- active pharmaceutical ingredient (API) manufacturing facilities at Srikakulum, Andhra Pradesh, and Miryalguda, Telengana, and Oncology formulation manufacturing facility at Duvadda, Visakhapatnam, Andhra Pradesh.
from Moneycontrol Business News https://www.moneycontrol.com/news/business/usfda-âcloses39-warning-letter-for-three-sitesdr-reddy39s-laboratories_14224201.html
Comments
Post a Comment